| View |
|
DR-XY43638
|
Iron Sucrose
|
Femorum
|
20mg/mL (100mg/5mL)
|
Solution For Iv Injection
|
Solution for IV Injection
|
Myungmoon Pharmaceutical Co., Ltd.
|
Korea
|
Renewal
|
28 March 2024
|
18 August 2029
|
| View |
|
DR-XY43639
|
Nimodipine
|
Nimopin
|
200mcg/mL (4mg/20mL)
|
Solution For Iv Infusion
|
Calcium Channel Blocker
|
Cisen Pharmaceutical Co., Ltd
|
China
|
Renewal
|
25 August 2024
|
15 August 2029
|
| View |
|
DR-XY43643
|
Gabapentin
|
Muzzapen-400
|
400 mg
|
Capsule
|
Anticonvulsant / Antiepileptic
|
Zest Pharma
|
India
|
Renewal
|
24 June 2024
|
18 August 2029
|
| View |
|
DR-XY43644
|
Propofol
|
Profogen
|
10 mg/mL
|
Emulsion For Injection (Iv)
|
General Anaesthetic
|
Xi' an Libang Pharmaceutical Co., Ltd.
|
China
|
Renewal
|
19 August 2024
|
18 August 2029
|
| View |
|
DR-XY43649
|
Imipenem + Cilastatin (as Sodium)
|
Imlastin
|
500mg/ 500mg
|
Powder For Injection (IV)
|
Antibacterial
|
Swiss Parenterals Pvt. Ltd.
|
India
|
Renewal
|
02 August 2024
|
19 August 2029
|
| View |
|
DR-XY43651
|
Meropenem (as trihydrate)
|
Merozil
|
1g
|
Powder for Injection (IV)
|
Antibacterial
|
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
|
China
|
Renewal
|
12 August 2024
|
20 August 2029
|
| View |
|
DR-XY43652
|
Terbinafine Hydrochloride
|
Finazyl
|
10mg/mL (1% w/v)
|
Topical Spray Solution
|
Antifungal
|
Shandong Jewin Pharmaceutical Co. Ltd.
|
China
|
Renewal
|
12 August 2024
|
20 August 2029
|
| View |
|
DR-XY43653
|
CEFIXIME(AS TRIHYDRATE)
|
CEFFIX
|
400MG
|
CAPSULE
|
ANTIBACTERIAL (CEPHALOSPORIN)
|
Medisure Laboratories Pakistan (Pvt.) Limited
|
Pakistan
|
Renewal
|
09 August 2022
|
26 August 2027
|
| View |
|
DR-XY43655
|
Ondansetron (as hydrochloride dihydrate)
|
Ondavell
|
2mg/mL (8mg/4mL)
|
Solution For Injection (IM/IV)
|
Antiemetic
|
PT. Novell Pharmaceutical Laboratories
|
Indonesia
|
Renewal
|
16 April 2024
|
22 August 2029
|
| View |
|
DR-XY43658
|
SODIUM ALGINATE + SODIUM BICARBONATE + CALCIUM CARBONATE
|
GAVISCON DOUBLE ACTION
|
250 mg/106.5 mg/187.5 mg
|
Chewable Tablet
|
Antacid/ Antireflux agent
|
Reckitt Benckiser Healthcare (UK) Limited
|
United Kingdom
|
Renewal
|
26 April 2024
|
22 August 2029
|
| View |
DR-XY43661_PI_01.pdf
|
DR-XY43661
|
Losartan potassium
|
Artosar 50
|
50 mg
|
Film-Coated Tablet
|
Angiotensin-2-Receptor Blocker
|
Zest Pharma
|
India
|
Renewal
|
11 June 2024
|
21 August 2029
|
| View |
|
DR-XY43662
|
Tramadol Hydrochloride
|
Tramklor
|
50mg/ml (100mg/2ml)
|
Solution for Injection (IM/IV/SC)
|
Opioid Analgesics
|
CSPC Ouyi Pharmaceutical Co. Ltd.
|
China
|
Renewal
|
05 May 2024
|
22 August 2029
|
| View |
|
DR-XY43663
|
Meropenem (as trihydrate)
|
Merozil
|
500mg
|
Powder for Injection (IV)
|
Antibacterial
|
Haikou Pharmaceutical Factory Co., Ltd.
|
China
|
Renewal
|
13 May 2024
|
22 August 2029
|
| View |
|
DR-XY43673
|
Cefixime (as trihydrate)
|
Ezcef
|
100mg/5mL
|
Powder for Suspension
|
Antibacterial (Cephalosporin)
|
Scott-Edil Advance Research Laboratories & Education Ltd.
|
India
|
Renewal
|
04 August 2024
|
03 September 2029
|
| View |
|
DR-XY43681
|
Gliclazide
|
Unbranded
|
80 mg
|
Modified-Release Tablet
|
Oral Hypoglycemic
|
Lloyd Laboratories, Inc.
|
Philippines
|
Renewal
|
04 August 2024
|
28 August 2029
|
| View |
|
DR-XY43682
|
Gliclazide
|
Unbranded
|
80 mg
|
Modified-Release Tablet
|
Oral Hypoglycemic
|
Lloyd Laboratories, Inc.
|
Philippines
|
Renewal
|
06 August 2024
|
28 August 2029
|
| View |
|
DR-XY43689 (For DOH Only)
|
Gliclazide
|
None
|
30 mg
|
Modified-Release Tablet
|
-
|
Lloyd Laboratories Inc.
|
Philippines
|
-
|
16 September 2020
|
28 August 2025
|
| View |
|
DR-XY43690(FOR DOH ONLY)
|
Metropolol tattrate
|
NONE
|
50 mg
|
Film Coated Tablet
|
-
|
Lloyd Laboratories, Inc.
|
Philippines
|
-
|
09 September 2020
|
02 February 2025
|
| View |
|
DR-XY43697
|
Ceftriaxone (As Sodium)
|
Cefkizon
|
500 mg
|
Powder For Injection (Im/Iv)
|
Antibacterial (Cephalosporin)
|
Samjin Pharmaceutical Co., Ltd.
|
Korea
|
Automatic Renewal
|
07 April 2022
|
03 September 2027
|
| View |
|
DR-XY43702
|
Gliclazide
|
Glitab
|
30 mg
|
Modified-Released Tablet
|
Oral Hypoglycemic
|
Lloyd Laboratories, Inc.
|
Philippines
|
Renewal
|
31 May 2024
|
03 September 2029
|